Original Article

You have full text access to this OnlineOpen article

Breast carcinoma survival in Europe and the United States

A population-based study

  1. Milena Sant M.D.1,†,*,
  2. Claudia Allemani Sc.D.1,
  3. Franco Berrino M.D.1,
  4. Michel P. Coleman M.D.2,
  5. Tiiu Aareleid M.D.3,4,
  6. Gilles Chaplain M.D.5,
  7. Jan Willem Coebergh M.D.6,
  8. Marc Colonna Ph.D.7,
  9. Paolo Crosignani M.D.8,
  10. Arlette Danzon M.D.9,
  11. Massimo Federico M.D.10,
  12. Lorenzo Gafà M.D.11,
  13. Pascale Grosclaude Ph.D.12,
  14. Guy Hédelin Ph.D.13,
  15. Josette Macè-Lesech M.Sc.14,
  16. Carmen Martinez Garcia M.D.15,
  17. Henrik Møller D.M.16,
  18. Eugenio Paci M.D.17,
  19. Nicole Raverdy M.Sc.18,
  20. Brigitte Tretarre M.D.19,
  21. Evelyn M. I. Williams M.D.20,
  22. European Concerted Action on Survival and Care of Cancer Patients (EUROCARE) Working Group‡

Article first published online: 29 DEC 2003

DOI: 10.1002/cncr.20038

Issue

Cancer

Cancer

Volume 100, Issue 4, pages 715–722, 15 February 2004

Additional Information

How to Cite

Sant, M., Allemani, C., Berrino, F., Coleman, M. P., Aareleid, T., Chaplain, G., Coebergh, J. W., Colonna, M., Crosignani, P., Danzon, A., Federico, M., Gafà, L., Grosclaude, P., Hédelin, G., Macè-Lesech, J., Garcia, C. M., Møller, H., Paci, E., Raverdy, N., Tretarre, B., Williams, E. M. I. and European Concerted Action on Survival and Care of Cancer Patients (EUROCARE) Working Group (2004), Breast carcinoma survival in Europe and the United States. Cancer, 100: 715–722. doi: 10.1002/cncr.20038

Author Information

  1. 1

    Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

  2. 2

    Cancer and Public Health Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom

  3. 3

    Department of Epidemiology and Biostatistics, Institute of Experimental and Clinical Medicine, Tallinn, Estonia

  4. 4

    Estonian Cancer Registry, North Estonian Regional Hospital Foundation's Cancer Centre, Tallinn, Estonia

  5. 5

    Côte d'Or Breast and Gynaecologic Cancer Registry, Centre Universitaire d'Epidémiologie de population, Faculté de Médicine, Dijon, France

  6. 6

    Comprehensive Cancer Centre South, Eindhoven Cancer Registry, Eindhoven, The Netherlands

  7. 7

    Isère Cancer Registry, Meylan, France

  8. 8

    Lombardy Cancer Registry, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

  9. 9

    Doubs Cancer Registry, Centre Hospitalo-Universitaire, Besanç, France

  10. 10

    Modena Cancer Registry, Policlinico, Modena, Italy

  11. 11

    Ragusa Cancer Registry, Ragusa, Italy

  12. 12

    Tarn Cancer Registry, Recherche en Epidémiologie et Prévention, Albi, France

  13. 13

    Bas-Rhin Cancer Registry, Laboratoire d'Epidémiologie et de Santé Publique, Faculté de Médecine, Strasbourg, France

  14. 14

    Calvados Cancer Registry, Centre François Baclesse, Caen, France

  15. 15

    Granada Cancer Registry, Escuela Andaluza de Salud Pública, Campus Universitario de Cartuja, Granada, Spain

  16. 16

    Thames Cancer Registry, London, United Kingdom

  17. 17

    Tuscany Cancer Registry, U.O. di Epidemiologia Clinica e Descrittiva, Firenze, Italy

  18. 18

    Somme Cancer Registry, Association pour la Recherche Epidemiologique en Picardie, Amiens, France

  19. 19

    Hérault Cancer Registry, Bât Recherche, Parc Euromédecine, Montpellier, France

  20. 20

    Mersey Cancer Registry, University of Liverpool, Liverpool, United Kingdom

  1. †

    Fax: 011-39-02-2668-1292

  2. ‡

    The EUROCARE Working Group for the current study includes the following contributors: Estonia: T. Aareleid and A. Kupp (Estonian Cancer Registry); France: G. Hèdelin (Bas Rhin Cancer Registry), G. Chaplain (Côte d'Or Breast and Gynaecologic Cancer Registry), M. Colonna and C. Exbrayat (Isère Cancer Registry), B. Tretarre (Hérault Cancer Registry), P. Grosclaude (Tarn Cancer Registry), J. Macè-Lesech (Calvados General Cancer Registry), M. Mercier (Doubs Cancer Registry), and N. Raverdy (Somme Cancer Registry); Italy: E. Artioli and M. Federico (Modena Cancer Registry), A. Barchielli and E. Paci (Tuscan Cancer Registry), F. Berrino (Project Leader), G. Gatta, M. Sant, and C. Allemani (Istituto Nazionale per lo Studio e la Cura dei Tumori), P. Crosignani, D. Speciale, M. R. Ruzza, and E. Frassoldi (Lombardy Cancer Registry), R. Capocaccia and A. Verdecchia (Istituto Superiore di Sanità), and L. Gafà, R. Tumino, and M. La Rosa (Ragusa Cancer Registry); Spain: C. Martinez (Granada Cancer Registry); The Netherlands: J.W.W. Coebergh and A. Voogd (Eindhoven Cancer Registry); United Kingdom: J. Bell and H. Møller (Thames Cancer Registry), M.P. Coleman (London School of Hygiene and Tropical Medicine), and E.M.I. Williams and J. Youngson (Merseyside and Cheshire Cancer Registry).

*Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I-20133 Milan, Italy

Publication History

  1. Issue published online: 3 FEB 2004
  2. Article first published online: 29 DEC 2003
  3. Manuscript Accepted: 17 NOV 2003
  4. Manuscript Revised: 14 NOV 2003
  5. Manuscript Received: 16 SEP 2003

Funded by

  • BIOMED Programme of the European Community
  • Europe Against Cancer Programme (European Breast Cancer Screening Network). Grant Number: 2000/CAN/201

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (114K)

REFERENCES

  • 1
    Gatta G, Capocaccia R, Coleman MP, et al. Toward a comparison of survival in American and European cancer patients. Cancer. 2000; 89: 893–900.
    Direct Link:
  • 2
    Sant M, Capocaccia R, Verdecchia A, et al. Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. Int J Cancer. 1998; 77: 679–683.
    Direct Link:
  • 3
    Quinn MJ, Martinez-Garcia C, Berrino F, EUROCARE Working Group. Variations in survival from breast cancer in Europe by age and country, 1978-1989. Eur J Cancer. 1998; 34: 2204–2211.
  • 4
    Sant M, EUROCARE Working Group. Differences in stage and therapy for breast cancer across Europe. Int J Cancer. 2001; 93: 894–901.
    Direct Link:
  • 5
    Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985; 312: 1604–1608.
  • 6
    Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003; 106: 416–422.
    Direct Link:
  • 7
    SpiesslB, BeahrsOH, HermanekP, et al., editors. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumors, 3rd ed. Berlin: Springer Verlag, 1992.
  • 8
    U.S. Department of Health and Human Services. National Cancer Institute, Surveillance, Epidemiology and End Results Program. SEER cancer statistics review, 1973-1999. [Dataset on CDROM]. Bethesda, MD: U.S. Department of Health and Human Services, 2001.
  • 9
    Ederer F, Axtell LM, Cutler SJ. The relative survival: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101–121.
  • 10
    Estève J, Benhamou E, Croasdale M, et al. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990; 9: 529–538.
    Direct Link:
  • 11
    Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Programs Biomed. 1985; 19: 197–207.
  • 12
    Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival analysis. Stat Med. 2004; 23: 51–64.
    Direct Link:
  • 13
    Tabar L, Fagerberg CJ, Gad A, Baldetorp L, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985; i: 829–832.
  • 14
    Tabar L, Fagerberg G, Duffy SW, et al. Update of the Swedish two-county program of mammographic screening for breast cancer. Radio Clin North Am. 1992; 30: 187–210.
  • 15
    Hakama M, Pukkala E, Heikkilä KV, et al. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ. 1997; 314: 864–867.
  • 16
    Blanks RG, Moss SM, McGahan CE, et al. Effect of NHS Breast Screening Programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ. 2000; 321: 665–669.
  • 17
    Botha JL, Bray F, Sankila R, et al. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003; 39: 1718–1729.
  • 18
    Coleman MP, Gatta G, Verdecchia A, et al. Cancer survival in Europe at the end of the 20th century. Ann Oncol. In Press.
  • 19
    BerrinoF, CapocacciaR, EstèveJ, et al., editors. Survival of cancer patients in Europe: the EUROCARE-2 study. IARC Scientific Pub. No. 151. Lyon: International Agency for Research on Cancer, 1999.
  • 20
    BerrinoF, SantM, VerdecchiaA, CapocacciaR, HakulinenT, EstèveJ, editors. Survival of cancer patients in Europe: the EUROCARE study. IARC Scientific Pub. No. 132. Lyon: International Agency for Research on Cancer, 1995.
  • 21
    Berrino F, Gatta G, Sant M, et al. The EUROCARE study of survival of cancer patients in Europe: aims, current status, strengths and weaknesses. Eur J Cancer. 2001; 37: 673–677.
  • 22
    Coleman MP, Babb P, Damiecki P, et al. Cancer survival trends in England and Wales 1971-1995: deprivation and NHS region. Series SMPS No. 61. London: The Stationery Office, 1999.
  • 23
    Coleman MP, Babb P, Quinn MJ, et al. Socio-economic inequalities in cancer survival in England and Wales. Cancer. 2001; 91: 208–216.
    Direct Link:
  • 24
    Chevarley F, White E. Recent trends in breast cancer mortality among white and black US women. Am J Public Health. 1997; 87: 775–781.
  • 25
    Mariotto A, Capocaccia R, Verdecchia A, et al. Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control. 2002; 13: 101–111.
  • 26
    Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment and survival by race and ethnicity. Arch Intern Med. 2003; 163: 49–56.
  • 27
    Potosky AL, Merrill RM, Riley GF, et al. Breast cancer survival and treatment in health maintenance organization and fee-for-service settings. J Natl Cancer Inst. 1997; 89: 1683–1691.
  • 28
    Lee-Feldstein A, Anton-Culver H, Feldstein PJ. Treatment differences and other prognostic factors related to breast cancer survival. Delivery systems and medical outcomes. JAMA. 1994; 271: 1163–1168.
  • 29
    Bradley CJ, Given CW, Roberts C. Race, socioeconomic status and breast cancer treatment and survival. J Natl Cancer Inst. 2002; 94: 490–496.
  • 30
    McDavid K, Tucker T, Sloggett A, et al. Does cancer survival in Kentucky depend on health insurance coverage? Arch Intern Med. In Press.
View Full Article (HTML) Get PDF (114K)